Allergy Immunotherapy Market to Surpass USD6.7B by 2031 as Biologics and SLIT Redefine Treatment

[Hyderabad, April 17th, 2025]– The global Allergy Immunotherapy Market, valued at USD 2.9 billion in 2023, is projected to grow at a rate of 10.8% to reach USD 6.7 billion by 2031, reports ClearView Market Insights. Biologic breakthroughs and patient-friendly SLIT tablets are replacing temporary symptom relief.
Request Sample @ https://clearviewmarketinsights.com/report-details/global-allergy-immunotherapy-market/
2024 Industry Milestones
- Biologics Revolution
- Palforzia® becomes the first biologic for Mn allergy.
- Viaskin™ Patch shows 88% efficacy in trials for milk allergy.
- SLIT Dominance
- Europe’s SLIT adherence hits 85%, doubling SCIT rates.
- 3 new FDA-fast-tracked SLIT tablets target pediatric allergies.
- Personalised Medicine
- mRNA Vaccines: ALK/Sanofi collaboration aims for 2027 launch.
Regional Leaders
- North America (45%): Biologic adoption (Palforzia®, Xolair®).
- Europe (XX%): SLIT tablet hub (Oralair®, Grastek®).
- Asia-Pacific (XX%): Rising pollution allergies (12% CAGR).
Executive Insights
“We’re transitioning from treating symptoms to reprogramming immune responses.”
– Carsten Hellmann, CEO, ALK-Abelló
Roadmap to 2031
- 2025: SLIT to overtake SCIT in revenue.
- 2027: 50% of food allergy patients on biologics/patches.
- 2030: Asia-Pacific market to triple with urbanization.
For more insights, visit https://clearviewmarketinsights.com/report-store
About Clearview Market Insights:
Clearview Market Insights is a leading market research and consulting firm providing in-depth industry analysis and strategic recommendations for businesses worldwide.
Media contact:
Bhavani K
Marketing and Sales Head
ClearView Market Insights
Mail: sales@clearviewmarketinsights.com
Phone: +1 917-993-7369